ANNOUNCEMENT: Goodbody Health products included on FSA Novel Foods Register

Goodbody Health Inc.
(“Goodbody” or “Goodbody Health” the “Company” or the “Group”)

31st March 2022

Goodbody Health products included on FSA Novel Food Register 

Goodbody Health (AQSE: GDBY) is pleased to announce that, following the UK Food Standard Agencies (FSA) publication of the Novel Foods approved list for CBD, the Company’s application has been authorised by the FSA to the next stage of the Novel Foods submission, being the publication of the Awaiting Evidence List. This means the FSA are now awaiting the final toxicology results and are satisfied with all the other evidence submitted. Once received, and if successful, the Company will progress onto the final Validated list.

The Company welcomes this increased compliance in the sector as the new regulations ensure that only fully compliant products are placed on the market. Those not included on these FSA Novel Food Validated or Awaiting Evidence lists will have to be taken off sale. Goodbody Health is now well placed to continue its growth in the CBD market as this process restricts the market to fewer competitors, as many did not meet the criteria. Consumers can visit, a site run by the Association for the Cannabinoid Industry (ACI), to see if a brand is compliant.

The Company’s extraction facility is HACCP, GMP and ISO 22000 certified and its laboratory is UKAS accredited against ISO 17025 international standard. Goodbody Health works closely with relevant regulatory bodies (FSA, Home Office, Trading Standards). Goodbody Health provides CBD extraction into isolate and distillate, manufacturing of CBD food supplements (oils, capsules, gummies, etc), cosmetics, and has a UKAS accredited analytical laboratory testing CBD products for potency and contaminants such as heavy metals, residual solvents, pesticides and microbials. In managing the whole production process, the Company tests the products at every stage of manufacturing, from extraction to the consumer product, ensuring all the products are of the highest quality.

Geremy Thomas, Executive Chairman, said: “The progression so far is very welcome, as after a significant amount of work and investment over the last 2 years, we can demonstrate our ambition of best quality, best price, guaranteed. We control every step of the process from extraction to shelf, and test through our accredited laboratory, to ensure every product that is made has achieved our ‘Gold Standard’, demonstrating that the Company meets legal and regulatory requirements.”

For further information:

Marc Howells
Chief Executive Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
[email protected]

AQSE Growth Market Corporate Advisor
Corporate Finance
Antonio Bossi / George Morgan
Arden Partners Ltd
+ 44 (0) 20 7614 5900

Anne Tew
Chief Financial Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
[email protected]

Share on

Published on